

Hong Kong Exchanges and Clearing Limited and The Stock Exchange of Hong Kong Limited take no responsibility for the contents of this announcement, make no representation as to its accuracy or completeness and expressly disclaim any liability whatsoever for any loss howsoever arising from or in reliance upon the whole or any part of the contents of this announcement.



Suzhou Basecare Medical Corporation Limited

蘇州貝康醫療股份有限公司

(A joint stock company incorporated in the People's Republic of China with limited liability)

(Stock Code: 2170)

**VOLUNTARY ANNOUNCEMENT
NMPA APPROVAL OF CLASS III MEDICAL DEVICE
REGISTRATION CERTIFICATES FOR
GEMS VITRIFICATION SET AND WARMING SET**

This announcement is made by Suzhou Basecare Medical Corporation Limited (the “**Company**”, together with its subsidiaries, the “**Group**”) on a voluntary basis to inform the shareholders and potential investors of the Company about the latest business advancement of the Group.

The board of directors (the “**Board**”) of the Company is pleased to announce that the Company recently obtained the Class III medical device registration certificates for the Vitrification Set and the Warming Set in its Gems series (registration certificate Nos.: Guo Xie Zhu Jin 20263180326 and Guo Xie Zhu Jin 20263180338, respectively) from the National Medical Products Administration of China (“**NMPA**”).

The Gems Vitrification-Warming Set originates from the same R&D system as the Gavi fully automated closed vitrification system. The complete reagent set is compatible with the Cryotop[®] carrier widely used in domestic reproductive centers, and with appropriate adjustments, it is also compatible with the Gavi fully automated vitrification instrument, accommodating both automated equipment and mainstream manual operation requirements in the laboratory.

In terms of formulation design, the Gems Vitrification Set employs a combination of two permeating cryoprotectants — DMSO and ethylene glycol. The dual permeating cryoprotectant formulation can effectively reduce the concentration of each individual agent, minimizing the toxicity risk of chemical substances to embryos while achieving excellent vitrification effect and inhibiting ice crystal formation. The synergistic action of the two components creates the preconditions for embryos to rapidly achieve vitrification under liquid nitrogen conditions. Regarding the non-permeating cryoprotectant, both the Gems Vitrification Set and the Warming Set use trehalose instead of traditional sucrose. Trehalose is a naturally derived disaccharide that does not penetrate into the cell interior, facilitating the formation of the vitrified state and reducing ice crystal generation. Throughout the entire cryopreservation and warming process, trehalose can stabilize the phospholipid bilayer of cell membranes and the structure of intracellular functional proteins. Compared to traditional sucrose formulations, trehalose provides more comprehensive protective effects for embryonic cells, reducing the risk of cellular damage during the warming process.

As of the date of this announcement, the Gems series of the Company has achieved registration and certification for multiple core reagents, with the product matrix continuously expanding. Certified products include Oocyte Retrieval Buffer, Sperm Wash Medium, Fertilisation Medium, Cleavage Medium, Blastocyst Medium, Embryo Medium and VitBase embryo processing fluid. Together with the newly approved Vitrification Set and Warming Set, the product chain now covers the entire core workflow from oocyte retrieval, sperm processing, fertilization, in vitro embryo culture, embryo cryopreservation to embryo warming. From gamete processing to embryo culture and development, and then to embryo cryopreservation and recovery, the Gems series has progressively established a complete product matrix for the embryo laboratory reagents.

Shareholders and potential investors of the Company are advised to exercise caution when dealing in the shares of the Company.

By order of the Board
Suzhou Basecare Medical Corporation Limited
Dr. Liang Bo
Chairman and General Manager

Suzhou, PRC, September 15, 2026

As at the date of this announcement, the Board comprises Dr. LIANG Bo, Mr. KONG Lingyin and Ms. JIANG Junchao as executive Directors; Mr. ZHAO Ye and Mr. WANG Weipeng as non-executive Directors; and Dr. KANG Xixiong, Mr. LAM Siu Wing and Dr. YEUNG Shu Biu William as independent non-executive Directors.